(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

HUMARK

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

HUMARK

ST13

US500000077898353

Class

42

Filing

77898353

Registration

3825025

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

28

Latest update

04/28/2021

Classification

Registered

Trademark type

Word

Nice classes

42

Filing date

12/21/2009

Registration date

07/27/2010

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

09/02/2020

Last transaction

09/02/2020

Responsible office

United States Patent and Trademark Office

Status code

800

Official register

Principal Register

First use anywhere

02/07/2009

First use in commerce

08/06/2009

Drawing code

4

Owner type

03

Owner location

Santa Clara, CA, US

Examiner

EISINGER,REBECCA MILES

Law office

L20

Current location

GENERIC WEB UPDATE

Holders and representatives

Holders

Crown Bioscience Inc.

Representatives

Yi Zhang

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Medical and scientific researchconducting preclinical drug studiesconsulting services in the field of medical and scientific researchproviding predictive modeling platforms and advice to translate preclinical drug study results into clinical design strategies for clinical trials; Conducting research and preclinical trials relating to pharmaceuticals in the field of translational oncology and drug development

Publications

History of USPTO decisions and trademark events.

28 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

04/28/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

04/28/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

04/28/2021

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

09/02/2020

RNL1

REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)

09/02/2020

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

09/02/2020

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

09/01/2020

E89R

TEAS SECTION 8 & 9 RECEIVED

07/26/2020

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

07/27/2019

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

09/28/2016

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

09/28/2016

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

09/28/2016

E815

TEAS SECTION 8 & 15 RECEIVED

07/22/2016

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

07/27/2015

R.PR

REGISTERED-PRINCIPAL REGISTER

07/27/2010

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/11/2010

PUBO

PUBLISHED FOR OPPOSITION

05/11/2010

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

04/08/2010

ALIE

ASSIGNED TO LIE

04/08/2010

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/22/2010

XAEC

EXAMINER'S AMENDMENT ENTERED

03/22/2010

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

03/22/2010

GNEA

EXAMINERS AMENDMENT E-MAILED

03/22/2010

CNEA

EXAMINERS AMENDMENT -WRITTEN

03/22/2010

DOCK

ASSIGNED TO EXAMINER

03/22/2010

MPMK

NOTICE OF PSEUDO MARK MAILED

12/30/2009

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/29/2009

NWAP

NEW APPLICATION ENTERED

12/24/2009

Continuous trademark protection

Get notified about every new filing that threatens HUMARK or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.